Summary & Overview
Non-Malignant Breast Disorders with CC/MCC: Inpatient Reimbursement Overview
DRG 600 addresses inpatient stays for non-malignant breast disorders that include a Complication or Comorbidity or Major Complication or Comorbidity, encompassing conditions like complicated mastitis or breast abscesses that require hospital-level care. This classification matters for inpatient reimbursement because the Centers for Medicare & Medicaid Services assigns higher payment weights to cases with increased clinical complexity and resource use.
DRG 600 Overview
DRG 600 covers inpatient admissions for non-malignant breast disorders when a Complication or Comorbidity or Major Complication or Comorbidity is present, including conditions such as severe mastitis, abscesses, or complicated benign breast masses requiring operative or medical management. This Diagnosis-Related Group is used by the Centers for Medicare & Medicaid Services to classify cases for Medicare payment and reflects higher resource use than non-complicated benign breast disorder admissions. The presence of a Complication or Comorbidity or Major Complication or Comorbidity increases expected inpatient resource intensity and impacts reimbursement relative to less complex breast disorder DRGs.
Clinical Trials
- Acute diagnostic and management strategies study: Trials comparing rapid in-hospital diagnostic pathways (for example, point-of-care ultrasound plus expedited pathology review versus standard outpatient workup) for patients admitted with acute non-malignant breast disorders such as abscess, severe mastitis, or complicated cysts. These studies enroll adult women and men presenting with acute breast pain, swelling, or infections requiring inpatient evaluation, and assess time to definitive diagnosis, length of stay, and rates of emergent procedures. Results are relevant to providers and payers because faster, accurate in-hospital diagnostics can reduce unnecessary admissions, shorten LOS, and target resource use for patients grouped under this DRG.
- Comparative effectiveness of procedural versus conservative inpatient management: Randomized or pragmatic trials comparing surgical drainage (bedside or operating room incision and drainage) versus image-guided percutaneous drainage or optimized antibiotic-only strategies for complicated benign breast infections and abscesses. These studies focus on patients hospitalized for non-malignant disorders with comorbidities (eg, diabetes, immunosuppression, recurrent abscess) to determine clinical resolution rates, complication and re-admission rates, and downstream care needs. Findings inform clinicians and payers about which in-hospital interventions lead to better short-term outcomes and lower total episode costs while minimizing complications that drive CC/MCC coding and resource intensity.
- Post-discharge outcomes and care coordination trials: Observational cohorts and interventional trials testing post-discharge follow-up models (early outpatient wound care clinics, telemedicine nursing check-ins, or structured antibiotic stewardship/transition-of-care programs) for patients discharged after inpatient treatment of non-malignant breast disorders. These studies enroll patients at discharge to evaluate 30-day readmission, wound healing, outpatient procedure rates, patient-reported outcomes, and overall post-acute utilization. This research is important to payers and providers because effective post-discharge programs can reduce readmissions, prevent escalation of care that increases DRG severity, and improve cost-effectiveness across the full episode of care.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.